文献速递白血病

低二倍体急性淋巴细胞白血病患儿的结局:一项回顾性跨国研究

Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Retrospective Multinational Study.
PubMed 文献 · J Clin Oncol · 2019-01-18

该回顾性跨国研究纳入1997至2013年间16个协作组或机构方案中的306例低二倍体急性淋巴细胞白血病患儿,分析预后因素及异基因造血细胞移植的作用。中位随访6.6年,272例可评估患者的5年无事件生存率为55.1%,5年总生存率为61.2%。诱导缓解结束时微小残留病(MRD)阴性、44条染色体的高二倍体亚型及按MRD分层方案治疗与较好预后相关;异基因移植相比单纯化疗未显著改善结局。

要点

  • 诱导缓解结束时MRD阴性的患儿5年无事件生存率为75%。
  • 44条染色体高二倍体亚型患儿5年无事件生存率为74%。
  • 按MRD分层方案治疗者5年无事件生存率为62%。

核心结论

  • 按MRD分层的治疗改善了低二倍体急性淋巴细胞白血病患儿的结局。
  • 异基因造血细胞移植总体上未显著改善结局,尤其在诱导后达到MRD阴性的患者中。

研究设计与样本

  • 回顾性跨国研究,收集1997年至2013年间16个协作组或机构方案中306例新诊断低二倍体急性淋巴细胞白血病患儿的数据。
  • 分析临床与生物学特征、基于MRD评估的早期治疗反应、是否采用MRD分层方案以及异基因移植对结局的影响。

主要发现

  • 中位随访6.6年,272例可评估患者的5年无事件生存率为55.1%(95%CI 49.3%至61.5%),5年总生存率为61.2%(95%CI 55.5%至67.4%)。
  • 诱导缓解结束时MRD阴性者5年无事件生存率为75%(95%CI 66.0%至85.0%)。
  • 44条染色体的高二倍体亚型者5年无事件生存率为74%(95%CI 61.0%至89.0%)。
  • 按MRD分层方案治疗者5年无事件生存率为62%(95%CI 55.0%至69.0%)。
  • 排除44条染色体高二倍体亚型患者并校正移植等待时间和协变量后,42例移植者与186例单纯化疗者的无病生存无显著差异(P=0.16),估计5年生存率分别为59%(95%CI 46.5%至75.0%)与51.5%(95%CI 44.7%至59.4%)。

关键数值与推荐

  • 诱导缓解结束时MRD阴性、44条染色体的高二倍体亚型及按MRD分层方案治疗与较好预后相关。
  • 异基因移植与单纯化疗相比,无病生存无显著差异(P=0.16),尤其在诱导后达到MRD阴性的亚组中。

临床怎么用

  • 作者认为按MRD分层的治疗改善了低二倍体急性淋巴细胞白血病患儿的结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We determined the prognostic factors and utility of allogeneic hematopoietic cell transplantation among children with newly diagnosed hypodiploid acute lymphoblastic leukemia (ALL) treated in contemporary clinical trials. PATIENTS AND METHODS: This retrospective study collected data on 306 patients with hypodiploid ALL who were enrolled in the protocols of 16 cooperative study groups or institutions between 1997 and 2013. The clinical and biologic characteristics, early therapeutic responses as determined by minimal residual disease (MRD) assessment, treatment with or without MRD-stratified protocols, and allogeneic transplantation were analyzed for their impact on outcome. RESULTS: With a median follow-up of 6.6 years, the 5-year event-free survival rate was 55.1% (95% CI, 49.3% to 61.5%), and the 5-year overall survival rate was 61.2% (95% CI, 55.5% to 67.4%) for the 272 evaluable patients. Negative MRD at the end of remission induction, high hypodiploidy with 44 chromosomes, and treatment in MRD-stratified protocols were associated with a favorable prognosis, with a 5-year event-free survival rate of 75% (95% CI, 66.0% to 85.0%), 74% (95% CI, 61.0% to 89.0%), and 62% (95% CI, 55.0% to 69.0%), respectively. After exclusion of patients with high hypodiploidy with 44 chromosomes and adjustment for waiting time to transplantation and for covariables in a Poisson model, disease-free survival did not differ significantly ( P = .16) between the 42 patients who underwent transplantation and the 186 patients who received chemotherapy only, with an estimated 5-year survival rate of 59% (95% CI, 46.5% to 75.0%) versus 51.5% (95% CI, 44.7% to 59.4%), respectively. Transplantation produced no significant impact on outcome compared with chemotherapy alone, especially among the subgroup of patients who achieved a negative MRD status upon completion of remission induction. CONCLUSION: MRD-stratified treatments improved the outcome for children with hypodiploid ALL. Allogeneic transplantation did not significantly improve outcome overall and, in particular, for patients who achieved MRD-negative status after induction.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Pui CH, Rebora P, Schrappe M, et al. Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Retrospective Multinational Study. J Clin Oncol. 2019. PMID: 30657737. doi:10.1200/JCO.18.00822

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。